Zhejiang Huahai Pharmaceutical 483, Nov 2016

Zhejiang Huahai Pharmaceutical 483, Nov 2016

Peter Baker FDA, Justin Boyd FDA$119.00

FDA investigators audited the Zhejiang Huahai Pharmaceutical facility in Taizhou, China and issued inspectional observations (via FDA 483) on 18 Nov 2016.

Buy This DocumentBuy 1-Year 483 Access

Product details

  • Inspection end: 18 Nov 2016
  • Location: Taizhou, China